KDR and small cell lung carcinoma: A different phase II trial investigated the association of olaparib with cediranib (a pan-VEGFR inhibitor) which affects sensitivity to PARPis via the downregulation of BRCA1-2 and RAD51 expression, in 25 patients with relapsed SCLC; they attained 8 PRs (28%) with a median duration of response (mDOR) of 3 months, mPFS of 4.1 months, and OS of 5.5 months, at a high cost of toxicity, with the rate of grade 3/4 AEs at 56%, the most common being hypertension, fatigue, and weight loss.